ClinicalTrials.gg
CompletedNCT05534022Updated Oct 13, 2026

Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression.

An interventional study of Test myopia control lenses (BSL) in Myopia, sponsored by Essilor International. Completed at 1 site in Singapore. Open to participants aged 8 Years to 13 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Essilor International · Not applicable, Interventional, and Treatment

How we know

Updated Oct 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
8 Years to 13 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Myopia by EssilorLuxottica — 13 open to participants now, 19 under way, none of them phase 3. Myopia · EssilorLuxottica.

Enrollment
17th of 28
40 · median 52
Started
2022
with 1 other
No phase
28 of 28
13 open now
Registered
4th of 28
by date

Among the 28 studies in Myopia by EssilorLuxottica, this one is the 17th largest by enrollment, is one of 2 that started in 2022, is one of 28 with no phase, and was the 4th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

13 of the 28 studies in Myopia by EssilorLuxottica are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 8 Years to 13 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Myopia by EssilorLuxottica, or all of them as a file.
02

Study summary

This is a mono-centre, prospective, one-arm, unmask clinical trial to evaluate the effectiveness of test lens in slowing myopia progression with respect to axial length elongation compared to a single vision spectacle lens from the historical control group of another clinical trial NCT05331378. A total of 40 children will be recruited.

Read the detailed description

As myopia is a growing worldwide problem, it is important to better understand the range of possible treatments to slow the progression of myopia. Spectacle lenses with aspherical lenslets were shown to be effective in reducing myopia progression and axial length elongation in children in the previous clinical trial (Bao et al. 2022). A dose-dependent effect was demonstrated, with higher lenslet asphericity having greater myopia control efficacy.

This open clinical trial will test the safety and effectiveness of a test lens designed to modify the area and amount of myopic defocus on the retina without compromising vision. The study population includes children in Singapore aged 8 to 13 years (40 subjects) at the time of commencing treatment. Axial length and spherical equivalent refraction will be the primary measure for myopia progression. Visual acuities will also be compared between test lenses and control lenses of the historical control group to determine the quality of vision using test lenses

03

Conditions studied

  • Myopia

Keywords

  • Refractive errors
  • Eye diseases
04

Who can participate

Ages eligible
8 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteer subject and guardian, fluent English spoken, willing to follow protocol and able to read, comprehend and sign the \& assent form.
  • Equal to or greater than 8 years and not older than 13 years at time of informed consent and assent.
  • Spherical equivalent refractive error (SER) by manifest refraction between -0.75 and -4.75 D in each eye.
  • Astigmatism, if present, of not more than 1.50 D.
  • Difference in SER between the two eyes (Anisometropia) by manifest refraction not more than 1.00 D.
  • Best corrected visual acuity in each eye equal to or better than +0.10 logMAR (≥ 20/25 as Snellen)
  • Be in good general health based on his/her and parent's/guardian's knowledge. Absence of ocular disease with full ophthalmic examination. Without any ocular or systemic condition known to affect refractive status.
  • Absence of strabismus by cover test at near or distance wearing correction.
  • Absence of amblyopia
  • Without ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state.

Exclusion criteria

Exclusion Criteria:

  • Vulnerability of subject
  • History of myopia control intervention
  • Participation in any clinical study within 30 days of the Baseline visit.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Test myopia control lenses (BSL)

    Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.

    Device: Test myopia control lenses (BSL)

Interventions

  • DeviceTest myopia control lenses (BSL)

    Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.

06

What researchers measure

Primary outcomes

  1. Axial Length

    Change in ocular axial length (mm)

    Time frame: 12 months and 24 months

Secondary outcomes

  1. Axial Length

    Change in ocular axial length (mm)

    Time frame: 6 months and 18 months

  2. Spherical Equivalent Refraction

    Change in spherical equivalent refraction (Dioptres) through manifest subjective refraction.

    Time frame: 6 months, 12 months, 18 months and 24 months

07

Study locations

1 site
  • Essilor R&D Centre Singapore
    Singapore, 339346, Singapore
08

References and documents

Publications

  • Bao J, Yang A, Huang Y, Li X, Pan Y, Ding C, Lim EW, Zheng J, Spiegel DP, Drobe B, Lu F, Chen H. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol. 2022 Aug;106(8):1171-1176. doi: 10.1136/bjophthalmol-2020-318367. Epub 2021 Apr 2. PubMed 33811039 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Feb 2025, 29 months.

Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 29 months is above that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2024 → Feb 2025 and completion Dec 2024 → Feb 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2022
First posted
Sep 9, 2022
StartActual
Sep 26, 2022
Primary completionActual
Feb 27, 2025was Dec 2024
CompletionActual
Feb 27, 2025was Dec 2024
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 13, 2026
Primary completion
Dec 2024→Feb 27, 2025 (actual)
Oct 13, 2026
Study completion
Dec 2024→Feb 27, 2025 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Active, not recruiting→Completed
    Primary completion Dec 2024→Feb 27, 2025 (now actual)
    Study completion Dec 2024→Feb 27, 2025 (now actual)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05534022
Responsible party
Sponsor
First posted
Sep 9, 2022
Start date
Sep 26, 2022
Primary completion
Feb 27, 2025
Completion
Feb 27, 2025
Last update
Oct 13, 2026

Study contacts

Wee Sing Ong
principal investigator · Essilor R&D Centre Singapore

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion